These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4730841)

  • 21. [Pharmacokinetics of cephalothin].
    Höffler D; Koeppe P; Fuchs E; Fiegel P
    Verh Dtsch Ges Inn Med; 1971; 77():1019-22. PubMed ID: 5005541
    [No Abstract]   [Full Text] [Related]  

  • 22. [Serum elimination of HES in moderately reduced renal function].
    Schimetta W; Kröll W; Pölz W; Colombo T; Gassmayr SE; Sirtl C; List WF
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Aug; 37(8):468-74. PubMed ID: 12165916
    [No Abstract]   [Full Text] [Related]  

  • 23. Creatinine clearance predicted from body cell mass is a good indicator of renal function.
    Donadio C; Lucchesi A; Tramonti G; Bianchi C
    Kidney Int Suppl; 1997 Dec; 63():S166-8. PubMed ID: 9407449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefadroxil kinetics in patients with impaired renal function.
    Cutler R
    J Int Med Res; 1980; 8(Suppl 1):17-20. PubMed ID: 7439499
    [No Abstract]   [Full Text] [Related]  

  • 25. [Significance of endogenous creatinine clearance in renal function studies].
    Veljović R; Nesić V
    Srp Arh Celok Lek; 1977; 105(7-8):637-44. PubMed ID: 607482
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function.
    Traeger A; Stein G; Sperschneider H; Keil E
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):481-6. PubMed ID: 6500766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the pharmacokinetics of latamoxef in normal and impaired renal function.
    Höffler D; Koeppe P; Moecke D
    Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy with cephaloridine in renal impairment.
    Bechtol LD
    Curr Ther Res Clin Exp; 1972 Dec; 14(12):790-800. PubMed ID: 4629818
    [No Abstract]   [Full Text] [Related]  

  • 30. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
    Lehne G; Nordal KP; Midtvedt K; Goggin T; Brosstad F
    Thromb Haemost; 1998 Jun; 79(6):1119-25. PubMed ID: 9657435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenous and oral pindolol in hypertensive patients with chronic renal failure.
    Safar ME; Chau NP; Levenson JA; Simon AC; Weiss YA
    Clin Sci Mol Med Suppl; 1978 Dec; 4():275s-277s. PubMed ID: 282067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of pindolol in patients with renal failure.
    Ohnhaus EE; Heidemann H; Meier J; Maurer G
    Eur J Clin Pharmacol; 1982; 22(5):423-8. PubMed ID: 7117354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Stereoselective determination of racemic pindolol in rat plasma and its application].
    Hasegawa R; Kushiya M; Komuro T; Isaka H
    Eisei Shikenjo Hokoku; 1987; (105):71-3. PubMed ID: 3449175
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics of pindolol in man.
    Gugler R; Herold W; Dengler HJ
    Eur J Clin Pharmacol; 1974; 7(1):17-24. PubMed ID: 4853602
    [No Abstract]   [Full Text] [Related]  

  • 35. Cephalexin in patients with renal disease.
    Linquist JA; Siddiqui JY; Smith IM
    N Engl J Med; 1970 Oct; 283(14):720-3. PubMed ID: 5454765
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug dosage in patients with renal disease.
    Dettli LC
    Clin Pharmacol Ther; 1974 Jul; 16(1):274-80. PubMed ID: 4843318
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma pindolol levels and their significance in the assessment of cardiac beta blockade.
    Bobik A; Jennings G; Korner PI
    Med J Aust; 1977 Sep; 2(SP2):3-5. PubMed ID: 927282
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function.
    Schönebeck J; Polak A; Fernex M; Scholer HJ
    Chemotherapy; 1973; 18(6):321-36. PubMed ID: 4741211
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function.
    Ohkawa M; Sugata T; Sawaki M; Okasho A; Kuroda K; Yamada H
    J Antimicrob Chemother; 1981 Dec; 8(6):447-51. PubMed ID: 7333988
    [No Abstract]   [Full Text] [Related]  

  • 40. Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.
    Meier J; Nüesch E
    Br J Clin Pharmacol; 1977 Jun; 4(3):371-2. PubMed ID: 901706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.